News In fiery SOTU, Biden proclaims “We finally beat big pharma” Just days after the US presidential race officially narrowed to a contest between President Joe Biden and former president Donald Trump, it’s no surprise that Biden’s State of the Union spe
R&D Big pharma places big bets on antibody-drug conjugates Antibody-drug conjugates have emerged as one of the most popular treatment modalities for investment in recent years.
R&D Universities and pharma companies need each other to create ... Academics and pharma executives seemingly live in very different worlds.
Market Access Big pharma is slimming down The last few years have been marked by many big pharma companies opting to move away from diversification and towards more focused operations.
Views & Analysis Keep it simple, scientists: AZ’s productivity push regains 1... AZ time management challenge has saved more than two million hours across the global company.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.